Biohaven Ltd.
Status: Publicly traded
Last reviewed: October 2026
Direct answer
Biohaven Ltd. is publicly traded on NYSE under the ticker BHVN.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial...
Can you invest in Biohaven Ltd.?
Yes. Biohaven Ltd. trades publicly on NYSE as BHVN.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Biohaven Ltd.
Detailed equity research is provided by MarketSnap.